Málaga, Spain

José Pavía Molina

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 8.0

ph-index = 1


Company Filing History:


Years Active: 2019

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: José Pavía Molina: Innovator in Multiple Sclerosis Treatment

Introduction

José Pavía Molina is a notable inventor based in Málaga, Spain. He has made significant contributions to the field of medical science, particularly in the treatment of multiple sclerosis. His innovative work has led to the development of a patented method that holds promise for improving the lives of those affected by this condition.

Latest Patents

José Pavía Molina holds a patent for "Methods for treating or ameliorating multiple sclerosis." This invention relates to a recombinant protein and its uses in the diagnosis and treatment of multiple sclerosis. Specifically, it involves the recombinant protein IFNAR2.3, along with antibodies and compositions that include this protein. The invention is particularly focused on methods for diagnosing multiple sclerosis and includes a diagnostic kit. Furthermore, it outlines the use of the protein IFNAR2.3 in preparing a medicament for treating multiple sclerosis.

Career Highlights

Throughout his career, José Pavía Molina has worked with esteemed institutions such as the University of Málaga and the Servicio Andaluz de Salud. His work in these organizations has allowed him to collaborate with other professionals in the field and contribute to advancements in medical research.

Collaborations

José has collaborated with notable colleagues, including Óscar Fernández Fernández and Begoña Oliver Martos. Their combined efforts have furthered research and development in the area of multiple sclerosis treatment.

Conclusion

José Pavía Molina's innovative contributions to the treatment of multiple sclerosis through his patented methods highlight his dedication to improving healthcare. His work continues to inspire advancements in medical science and offers hope for those affected by this challenging condition.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…